Amicus Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $185,212 | $169,061 | $154,688 | $125,249 |
Gross Profit | 156,768 | 147,720 | 139,471 | 113,551 |
EBITDA | 16,468 | 47,859 | -5,764 | -4,753 |
EBIT | 14,571 | 45,985 | -7,616 | -6,590 |
Net Income | 1,690 | 17,306 | -24,420 | -21,686 |
Net Change In Cash | 185,212 | 169,061 | 154,688 | 125,249 |
Free Cash Flow | 15,954 | 35,278 | -28,929 | 7,546 |
Cash | 214,010 | 190,553 | 158,702 | 181,657 |
Basic Shares | 314,355 | 310,433 | 308,254 | 307,689 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $634,210 | $528,295 | $399,356 | $329,233 |
Gross Profit | 553,821 | 475,352 | 362,030 | 290,634 |
EBITDA | 53,810 | 29,389 | -92,079 | -199,578 |
EBIT | 46,350 | 20,842 | -99,952 | -204,920 |
Net Income | -27,110 | -56,106 | -151,584 | -236,568 |
Net Change In Cash | 634,210 | 528,295 | 399,356 | 329,233 |
Cost of Revenue | -81,722 | |||
Free Cash Flow | 29,849 | -37,444 | -76,531 | -170,341 |
Cash | 214,010 | 213,752 | 246,994 | 148,813 |
Basic Shares | 308,363 | 304,380 | 295,164 | 289,057 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | $0.10 |
2025-09-30 | $0.06 |
2025-06-30 | -$0.08 |
